Cannabinoids, most notably CBD and THCa, have been used for many years in cancer therapy.
A study by the Ohio State University Medical Center has shown promise and positive correlation between the treatment of breast cancer with the use of cannabis, specifically with doses of the non-psychoactive cannabinoid, CBD.
Cannabinoids have been shown to possess anti-proliferative and anti-angiogenic effects in vitro as well as in vivo in different cancer models. Cannabinoids regulate key cell signaling pathways that are involved in cell survival, invasion, angiogenesis, metastasis, etc. There is more focus on CB1 and CB2, the two cannabinoid receptors which are activated by most of the cannabinoids.
The University's review article focuses on a broad range of cannabinoids, their receptor dependent and receptor independent functional roles against various cancer types with respect to growth, metastasis, energy metabolism, immune environment, stemness and future perspectives in exploring new possible therapeutic opportunities.